CA2278189A1 - Cellules a peptides ou a antigenes charges de peptides - Google Patents

Cellules a peptides ou a antigenes charges de peptides Download PDF

Info

Publication number
CA2278189A1
CA2278189A1 CA002278189A CA2278189A CA2278189A1 CA 2278189 A1 CA2278189 A1 CA 2278189A1 CA 002278189 A CA002278189 A CA 002278189A CA 2278189 A CA2278189 A CA 2278189A CA 2278189 A1 CA2278189 A1 CA 2278189A1
Authority
CA
Canada
Prior art keywords
cells
peptide
ctl
peptides
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002278189A
Other languages
English (en)
Inventor
Van Tsai
Scott Southwood
John Sidney
Alessandro Sette
Estaban Celis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2278189A1 publication Critical patent/CA2278189A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un procédé d'obtention in vitro de lymphocytes T cytotoxiques (CTL) spécifiques d'antigènes présenté en association avec les méthodes d'utilisation in vivo desdits lymphocytes à des fins thérapeutiques. Les cellules porteuses d'antigènes (APC) utilisées dans ces travaux comportent notamment des cellules dendritiques prétraitées par du GM-CSF et de l'IL-4. Les cellules CTL spécifiques d'un antigène ont été obtenues par incubation de préparations de CD8 en présence de cellules APC qui fixent les peptides désirés. L'IL-7 était généralement ajouté au jour 1 de l'incubation, et l'IL-10 était généralement ajouté un jour plus tard, et pendant la restimulation. L'invention porte également sur des procédés d'utilisation de cellules dendritiques pulsées par peptides pour identifier des antigènes tumoraux restreints au CMH de classe I, et des épitopes subdominants.
CA002278189A 1997-01-31 1998-01-30 Cellules a peptides ou a antigenes charges de peptides Abandoned CA2278189A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3669697P 1997-01-31 1997-01-31
US60/036,696 1997-01-31
PCT/US1998/001959 WO1998033888A1 (fr) 1997-01-31 1998-01-30 Cellules a peptides ou a antigenes charges de peptides

Publications (1)

Publication Number Publication Date
CA2278189A1 true CA2278189A1 (fr) 1998-08-06

Family

ID=21890106

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002278189A Abandoned CA2278189A1 (fr) 1997-01-31 1998-01-30 Cellules a peptides ou a antigenes charges de peptides

Country Status (5)

Country Link
EP (1) EP1012238A4 (fr)
JP (1) JP2001509677A (fr)
AU (1) AU6140998A (fr)
CA (1) CA2278189A1 (fr)
WO (1) WO1998033888A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
ATE512666T1 (de) * 1999-06-29 2011-07-15 Epimmune Inc Hla-bindende peptide und ihre verwendungen
EP1230268B1 (fr) 1999-11-18 2009-10-14 Pharmexa Inc. Analogues heteroclites de classe i epitopes
EP1235848A4 (fr) * 1999-12-10 2005-02-09 Epimmune Inc Induction de reponses immunes cellulaires a l'antigene carcinoembryonnaire a l'aide des compositions renfermant des peptides et des acides nucleiques
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
EP1303287A4 (fr) * 2000-06-16 2006-02-08 Argonex Pharmaceuticals Peptides mhc surexprimes sur des cellules cancereuses de la prostate et methodes d'utilisation
EP1312670A4 (fr) * 2000-08-16 2005-11-30 Takara Bio Inc Procede de culture extensive de lymphocytes t cytotoxiques specifiques de l'antigene
CA2420225A1 (fr) * 2000-09-01 2002-03-14 Pharmexa Inc. Peptides de fixation de hla-a2.1 et leurs utilisations
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
KR100888915B1 (ko) 2001-08-15 2009-03-16 다카라 바이오 가부시키가이샤 항원특이적 세포상해성 ｔ 세포 확대배양방법
JP4406566B2 (ja) 2002-03-25 2010-01-27 タカラバイオ株式会社 細胞傷害性リンパ球の製造方法
PT1620456E (pt) 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
WO2005007694A1 (fr) * 2003-07-16 2005-01-27 Green Peptide Co., Ltd. Peptide her2/neu et utilisation therapeutique de celui-ci
KR101331746B1 (ko) 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
EP1715343B1 (fr) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Méthode d'identification des épitopes en rapport avec l'immunogénicité des produits bio-pharmaceutiques
EP1916302A4 (fr) 2005-08-17 2009-10-21 Takara Bio Inc Procedede production de lymphocytes
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
AU2012258603A1 (en) 2011-05-26 2014-01-16 Geneius Biotechnology, Inc. Modulated immunodominance therapy
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
KR101749195B1 (ko) 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
EP3350600A4 (fr) 2015-09-18 2019-04-17 Baylor College of Medicine Identification d'antigène immunogène à partir d'un pathogène et corrélation avec l'efficacité clinique
CN105175527B (zh) * 2015-10-09 2021-06-04 深圳市康尔诺生物技术有限公司 一种乳腺癌特异性的热休克蛋白复合物及其应用
JP7019578B2 (ja) * 2015-12-30 2022-02-15 セルジーン コーポレイション Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球
US12247053B2 (en) 2018-10-26 2025-03-11 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003205A1 (fr) * 1992-08-07 1994-02-17 Cytel Corporation Peptides de liaison de hla, et leurs utilisations

Also Published As

Publication number Publication date
WO1998033888A1 (fr) 1998-08-06
EP1012238A1 (fr) 2000-06-28
AU6140998A (en) 1998-08-25
JP2001509677A (ja) 2001-07-24
EP1012238A4 (fr) 2003-03-05

Similar Documents

Publication Publication Date Title
CA2278189A1 (fr) Cellules a peptides ou a antigenes charges de peptides
EP0726941B1 (fr) Procedes de therapie (ex-vivo) recourant a des cellules presentatrices d'antigenes porteurs de peptides pour activer des ctl
US6077519A (en) Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
KR101008245B1 (ko) 세포 상해성 ｔ 림프구
CA2700436C (fr) Vaccins contre le cancer et methodes de vaccination
Bakker et al. Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope
Santegoets et al. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line
Agrawal et al. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors
US20030077289A1 (en) Use of cell-penetrating peptides to generate antitumor immunity
WO1994002156A1 (fr) Procedes d'utilisation de cellules dendritiques pour activer des lymphocytes t
KR20180063841A (ko) Ｔ 세포 자극용 엑소좀 및 이의 약제학적 용도
US6821778B1 (en) Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
WO2010129895A2 (fr) Epitopes des cd133
Perez et al. HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones
US20150218248A1 (en) Antigen Peptide Originated From T790M Point-Mutated Sequence of Epidermal Growth Factor Receptor
US20170088601A1 (en) Cd133 epitopes
Abdel-Wahab et al. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide (280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity
Okugawa et al. A novel human HER2‐derived peptide homologous to the mouse Kd‐restricted tumor rejection antigen can induce HLA‐A24‐restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals
WO1999050637A2 (fr) Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes
Met et al. Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC
JP5155368B2 (ja) 細胞傷害性ｔリンパ球
Shimono et al. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells
Heike et al. Membranes activate tumor-and virus-specific precursor cytotoxic T lymphocytes in vivo and stimulate tumor-specific T lymphocytes in vitro: implications for vaccination
Mitchell et al. The cytotoxic T cell response to peptide analogs of the HLA-A* 0201-restricted MUC1 signal sequence epitope, M1. 2
Borras-Cuesta et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen

Legal Events

Date Code Title Description
FZDE Discontinued